Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Inv. presentation
MERRIMACK PHARMACEUTICALS INC (MACK) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Merrimack Reports Second Quarter 2023 Financial Results"
06/07/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/04/2023 8-K Quarterly results
03/09/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Merrimack Reports Full Year 2022 Financial Results"
12/05/2022 8-K Quarterly results
11/09/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
08/03/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/27/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Amendment to Amendend and Restated Bylaws of the Registrant"
03/09/2022 8-K Quarterly results
08/05/2021 8-K Quarterly results
08/05/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Merrimack Reports Second Quarter 2021 Financial Results"
06/14/2021 8-K Quarterly results
03/11/2021 8-K Quarterly results
11/05/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Merrimack Reports Third Quarter 2020 Financial Results"
08/07/2020 8-K Quarterly results
05/28/2020 8-K Submission of Matters to a Vote of Security Holders
03/30/2020 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhi...
Docs: "Asset Purchase Agreement, between Merrimack Pharmaceuticals, Inc. and Celator Pharmaceuticals, Inc"
02/21/2020 8-K Quarterly results
12/03/2019 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I...
Docs: "Certificate of Designation of Series Z Junior Preferred Stock of Merrimack Pharmaceuticals, Inc., as filed with the Secretary of State of the State of Delaware on December 3, 2019",
"Section 382 Rights Agreement, between Merrimack Pharmaceuticals, Inc. and Computershare Trust Company, N.A., as Rights Agent",
"MERRIMACK PHARMACEUTICALS ADOPTS SECTION 382 NET OPERATING LOSS RIGHTS PLAN"
10/21/2019 8-K Quarterly results
09/20/2019 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : September 17, 2019 Merrimack Pharmaceuticals, Inc. Delaware 001-35409 04-3210530 One Broadway, 14th Floor Cambridge, MA 02142 Registrant's telephone number, including area code: 441-1000",
"Cooperation Agreement, by and among the Company, Newtyn Management, LLC, Newtyn Partners, LP, Newtyn TE Partners, LP, Noah G. Levy, Newtyn Capital Partners, LP, Ledo Capital, LLC, Western Standard, LLC, Western Standard Partners, LP, Western Standard Partners QP, LP and Eric D. Andersen",
"Merrimack Pharmaceuticals Announces Changes to Board of Directors"
07/26/2019 8-K Changes in Registrant's Certifying Accountant
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : July 24, 2019 Merrimack Pharmaceuticals, Inc. Delaware 001-35409 04-3210530 One Broadway, 14 th Floor Cambridge, MA 02142 Registrant's telephone number, including area code: 441-1000"
07/17/2019 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
Docs: "Letter from PricewaterhouseCoopers LLP, to the Securities and Exchange Commission regarding statements included in this Current Report on Form 8-K"
07/12/2019 8-K Completion of Acquisition or Disposition of Assets
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : July 12, 2019 Merrimack Pharmaceuticals, Inc. Delaware 001-35409 04-3210530 One Broadway, 14 th Floor Cambridge, MA 02142 Registrant's telephone number, including area code: 441-1000"
07/01/2019 8-K/A Cost Associated with Exit or Disposal Activities
Docs: "8-K/A"
07/01/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FORM 8-K"
07/01/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Amendment No. 2 to Asset Purchase Agreement, between Merrimack Pharmaceuticals, Inc. and 14ner Oncology, Inc",
"Amendment No. 2 to Asset Purchase Agreement, between Merrimack Pharmaceuticals, Inc. and 14ner Oncology, Inc"
06/24/2019 8-K Quarterly results
05/30/2019 8-K Entry into a Material Definitive Agreement, Cost Associated with Exit or Disposal Activities, Departure of Directors or Certa...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 23, 2019 Merrimack Pharmaceuticals, Inc. Delaware 001-35409 04-3210530 One Kendall Square, Suite B7201 Cambridge, MA 02139 Registrant's telephone number, including area code: 441-1000",
"Asset Purchase Agreement, by and between Merrimack Pharmaceuticals, Inc. and 14ner Oncology, Inc",
"Merrimack Pharmaceuticals Announces Completion of Strategic Review, Preservation of Ipsen Milestones and Special Cash Dividend"
05/10/2019 8-K Quarterly results
Docs: "Merrimack Reports First Quarter 2019 Financial Results"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy